Management of Acute Symptomatic CMV Infection
For acute symptomatic CMV infection (CMV disease), initiate treatment with intravenous ganciclovir or oral valganciclovir as first-line therapy, continuing at full doses until symptom resolution and viral clearance from blood. 1
First-Line Treatment Approach
The treatment strategy depends on disease severity and patient factors:
Mild to Moderate Disease
- Oral valganciclovir is appropriate for mild CMV disease in immunosuppressed patients 2
- This includes CMV retinitis in AIDS patients where valganciclovir can be started initially 2
Severe or Tissue-Invasive Disease
- Intravenous ganciclovir or foscarnet at full doses (adjusted for renal function) is preferred 2
- Continue full-dose treatment until:
- Complete symptom resolution
- Clearance of blood antigenemia or DNAemia 2
Special Considerations for Drug Selection
Neutropenic patients: If valganciclovir cannot be used due to neutropenia, consider maribavir 1
Renal impairment: If foscarnet is inappropriate for patients with renal dysfunction, maribavir should be considered 1
Important caveat: Maribavir has poor CNS and ocular penetration, so it should not be used for CMV disease involving the brain or eyes 1
Monitoring During Treatment
Close monitoring is essential for:
- Drug side effects (particularly myelosuppression with ganciclovir, nephrotoxicity with foscarnet)
- Treatment response via CMV DNAemia quantification
- Clinical symptom improvement 2
Refractory or Resistant Disease
If CMV disease persists or progresses despite first-line therapy:
Second-line therapy: Maribavir is recommended for resistant or refractory CMV infections, as it demonstrated higher response rates and lower organ toxicity compared to investigator-assigned alternatives 1, 3
Alternative approaches for refractory disease:
- High-dose ganciclovir (7.5-10.0 mg/kg every 12 hours, if tolerated and no CMV disease present) 1
- Combination therapy with ganciclovir plus foscarnet for drug-resistant CMV 2
- Check for resistance mutations via genotyping to guide therapy selection 1
Unconventional agents (for extreme cases): leflunomide, artesunate, or CMV-specific T-cell therapy may be considered 1, 2
Pediatric Considerations
Recommendations for children do not differ substantially from adults, though maribavir is FDA-approved only for children ≥12 years (not approved by European Medicines Agency for this age group) 1
Critical Pitfalls to Avoid
- Do not use maribavir for CNS or ocular CMV disease due to poor tissue penetration 1
- Do not combine maribavir with valganciclovir or ganciclovir - this combination is not recommended 1
- Maribavir has a lower threshold for resistance development compared to other antivirals 1
- Always pursue immune reconstitution when possible through reduction of immunosuppression or initiation of antiretroviral therapy 2